Search research articles
Contact Us
Filters
Showing results (441-450 of 512) with videos related to
Page
of 52
Sort By:
Therapeutic Advances in Medical Oncology
|
June 30, 2025
Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)
Miguel García-Pardo, Marta García de Herreros, Edouard Auclin, et al.
Nature Cancer
|
February 5, 2022
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort
Laurence Albiges, Stéphanie Foulon, Arnaud Bayle, et al.
Nature Communications
|
October 4, 2024
The genomic and transcriptomic landscape of metastastic urothelial cancer
Yohann Loriot, Maud Kamal, Laurene Syx, et al.
The Lancet. Oncology
|
July 3, 2026
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial
Leonardo Brunetti, Valentina Santo, David J Pinato, et al.
Nature Communications
|
October 31, 2024
Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer
Yohann Loriot, Maud Kamal, Laurene Syx, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
Giuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.
Clinical Lung Cancer
|
November 5, 2025
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies
Bob T Li, Leena Gandhi, Vignesh Ravichandran, et al.
JCO Precision Oncology
|
January 20, 2022
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy
Roberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
Cancer Discovery
|
December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Alexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
JAMA Oncology
|
May 29, 2025
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer
Arianna Marinello, Maria Rosa Ghigna, Julia K Rotow, et al.
Page
of 52
Search research articles
Search
Showing results (441-450 of 512) with videos related to
Sort By:
Page
of 52
Therapeutic Advances in Medical Oncology
|
June 30, 2025
Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)
Miguel García-Pardo, Marta García de Herreros, Edouard Auclin, et al.
Nature Cancer
|
February 5, 2022
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort
Laurence Albiges, Stéphanie Foulon, Arnaud Bayle, et al.
Nature Communications
|
October 4, 2024
The genomic and transcriptomic landscape of metastastic urothelial cancer
Yohann Loriot, Maud Kamal, Laurene Syx, et al.
The Lancet. Oncology
|
July 3, 2026
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial
Leonardo Brunetti, Valentina Santo, David J Pinato, et al.
Nature Communications
|
October 31, 2024
Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer
Yohann Loriot, Maud Kamal, Laurene Syx, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
Giuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.
Clinical Lung Cancer
|
November 5, 2025
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies
Bob T Li, Leena Gandhi, Vignesh Ravichandran, et al.
JCO Precision Oncology
|
January 20, 2022
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy
Roberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
Cancer Discovery
|
December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Alexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
JAMA Oncology
|
May 29, 2025
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer
Arianna Marinello, Maria Rosa Ghigna, Julia K Rotow, et al.
Page
of 52